Since both inflammation in adipose tissue and insulin resistance are key problems in obesity, there is a rationale for the development of novel, GPR120-based therapies for overweight and obese individuals. The gene discussed is FFAR4; the disease is obesity due to melanocortin 4 receptor deficiency.